Back to results

Comparative Outcomes Management With Electronic Data Technology (COMET) Study (COMET)

Primary Purpose

Sleep Apnea, Obstructive

Status

Completed

Phase

Not Applicable

Locations

United States

Study Type

Interventional

Intervention

Positive Airway Pressure (PAP)

Oral Appliance (OA)

About this trial

This is an interventional treatment trial for Sleep Apnea, Obstructive focused on measuring Obstructive Sleep Apnea, Obstructive Sleep Apnea Syndrome, Sleep Apnea Syndrome, Obstructive, Syndrome, Obstructive Sleep Apnea, Syndrome, Sleep Apnea, Obstructive, Syndrome, Upper Airway Resistance, Sleep Apnea, Upper Airway Resistance Sleep Apnea Syndrome

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Age > 18 years.
BMI > = 25.0 kg/m^2.
A diagnosis of obstructive sleep apnea based upon medical history and apnea- hypopnea index > = 10.0 or oxygen desaturation index (ODI; ≥4%) ≥ 10.0 on Diagnostic Polysomnogram.
Report a history of hypertension (or need for treatment for hypertension) which is currently untreated OR taking medication for the treatment of hypertension.
Stable medication regimen for 2 months prior to the Baseline Testing Visit. As-needed medications such as those used for allergy, cold, or minor pain symptoms may be used at the discretion of the Clinical Center physician.

Exclusion Criteria:

Cardiovascular disease which, in the judgment of the investigator, if observed during standard clinical practice would lead the treating physician to make every effort to treat the patient's sleep apnea with positive airway pressure, rather than alternative treatments.
Clinically significant acute or chronic disease that is not well controlled or could affect ability to complete or comply with study procedures, in the opinion of the Clinical Center physician.
Respiratory disease requiring supplemental oxygen or medication. Individuals with asthma may be included at the discretion of the Clinical Center physician if disease is well controlled and medications are stable for 2 months.
History of (within 12 months prior to enrollment), or current diagnosis of, Axis I or Axis II psychiatric disorder (other than obstructive sleep apnea) that in the opinion of the Clinical Center physician would affect ability to complete or comply with study procedures (e.g., schizophrenia and other psychotic disorders).
History of (within 3 months prior to enrollment), or current diagnosis of narcolepsy, idiopathic hypersomnia, restless legs syndrome, rapid eye movement (REM) behavior disorder, persistent situational insomnia, or sleep-related breathing disorders other than obstructive sleep apnea.
Periodic limb movement arousal index > 10.0 on the Diagnostic Polysomnogram.
Significant daytime sleepiness at study entry as indicated by:
- an Epworth Sleepiness Scale total score > 16, or a score of 3 (high chance) on the question about risk of dozing "In a car, while stopped for a few minutes in traffic" or
- a report of falling asleep at the wheel, a motor vehicle accident, or near-miss accident due to sleepiness in the past 24 months, which in the judgment of the study physician was not attributable to acute sleep loss.
Oxygen saturation < 80% for > 10% of sleep time during the Diagnostic Polysomnogram, or intervention with positive airway pressure or oxygen for safety purposes during the Diagnostic Polysomnogram.
Any prior treatment for obstructive sleep apnea with positive airway pressure or oral appliance, or surgical treatment for obstructive sleep apnea in the past year.
Contraindication for treatment with either positive airway pressure or oral appliance, in the opinion of the Clinical Center physician or dentist, including significant nasal obstruction, insufficient or loose teeth, dentures, advanced periodontal disease, or significant temporomandibular joint pain.
Pregnancy.
Difficulty understanding or speaking English, or inability to read and understand informed consent and study procedures.
Significant vision, hearing, or motor problems that, in the opinion of the Clinical Center physician, would affect ability to complete study procedures.
A work schedule that does not allow for nighttime sleep on the 3 nights before each study visit.
Current or planned participation in another research study.
Metal objects, devices, or implants that are in or on the body (Stanford Clinical Center only).
Creatinine clearance <30 and creatinine >1.6 (Stanford Clinical Center only).
Upper arm circumference > 20 inches

Sites / Locations

Stanford Sleep Medicine Center
Harvard Brigham and Women's Hospital
Center for Sleep and Circadian Neurobiology, University of Pennsylvania School of Medicine
University of Wisconsin-Madison School of Medicine, Department of Psychiatry

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Arm Label

Positive Airway Pressure

Oral Appliance

Arm Description

Participants randomized to standard clinical Positive Airway Pressure (PAP) treatment for Obstructive Sleep Apnea (OSA).

Subjects randomized to standard Oral Appliance (OA) treatment for Obstructive Sleep Apnea (OSA).

Outcomes

Primary Outcome Measures

Nocturnal Mean Arterial Blood Pressure (NMAP) at 2 Months

Mean arterial blood pressure during the sleep period as recorded by 24-hour ambulatory blood pressure monitoring after approximately 2 months of treatment

Secondary Outcome Measures

Nocturnal Mean Arterial Blood Pressure (NMAP) at 6 Months

Nocturnal mean arterial blood pressure as recorded by 24-hour ambulatory blood pressure monitoring after approximately 6 months of treatment

Ratio of Nocturnal Mean Arterial Pressure (NMAP) to Daytime Mean Arterial Pressure at 2 Months

Ratio of NMAP to mean daytime arterial pressure, expressed as a percentage at the 2 month visit for PAP and OA arms. The ratio is calculated by dividing the NMAP by the daytime mean arterial pressure; the result is then multiplied by 100 to obtain a percentage.

Ratio of NMAP to Daytime Mean Arterial Pressure at 6 Months

Ratio of NMAP to daytime mean arterial pressure, expressed as a percentage at the 6 month visit for PAP and OA arms. The ratio is calculated by dividing the NMAP by the daytime mean arterial pressure; the result is then multiplied by 100 to obtain a percentage.

Mean Absolute Flow-Mediated Vasodilatation of the Brachial Artery by Vascular Ultrasound

Mean absolute flow-mediated vasodilatation (FMD) of the brachial artery (i.e., the mean change in brachial artery diameter [in millimeters] from baseline to the value that is obtained after the cuff deflation) as measured by vascular ultrasound (VU) at the 6-month visit

Mean Relative Flow-Mediated Vasodilatation of the Brachial Artery by Vascular Ultrasound

Mean relative flow-mediated vasodilatation (FMD) of the brachial artery (i.e., the mean change in brachial artery diameter from baseline to the value that is obtained after the cuff deflation, divided by the baseline value and multiplied by 100) as measured by vascular ultrasound (VU) at the 6-month visit

Full Information

NCT ID

NCT01461473

First Posted

October 20, 2011

Last Updated

April 14, 2017

Sponsor

Stanford University

1. Study Identification

Unique Protocol Identification Number

NCT01461473

Brief Title

Comparative Outcomes Management With Electronic Data Technology (COMET) Study

Acronym

COMET

Official Title

R01: Comparative Outcomes Management With Electronic Data Technology (COMET) Study

Study Type

Interventional

2. Study Status

Record Verification Date

April 2017

Overall Recruitment Status

Completed

Study Start Date

December 2011 (undefined)

Primary Completion Date

May 2014 (Actual)

Study Completion Date

June 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Principal Investigator

Name of the Sponsor

Stanford University

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

STAGE I of the COMET study was to develop an Electronic Network Informatics Infrastructure that prospectively enabled access to and the sharing of clinical and research data. STAGE II: This was a Comparative Effectiveness Trial (CET) evaluating positive airway pressure (PAP) vs. oral appliance (OA) therapy in improving hypertension and abnormalities in cardiovascular function in overweight/obese patients with obstructive sleep apnea (OSA). Data collected during the STAGE II study was incorporated in Part 3 of the STAGE I study. STAGE III of the COMET study was completion of data analysis and preparation of the electronic network informatics infrastructure for use beyond the four Clinical Centers to interested CTSA institutions. We also explored expanding ontologies, and the use of federated database methodology.

Detailed Description

STAGE I, Part 1: We extracted limited access data sets from an existing research database (prior research patients' data from APPLES research project, where patients consented to provide a limited access data sets to the public domain as required by grants funded by the National Heart, Lung, and Blood Institute [NHLBI], PI: Dr. Clete Kushida) and a dummy database with prepared test data (no real patient data) to evaluate and refine the initial iterations of the informatics infrastructure created via an agile evolutionary development process. STAGE I, Part 2: We expanded the functionality of the informatics infrastructure by testing its ability to incorporate research data collected from an electronic questionnaire, the Alliance Sleep Questionnaire (ASQ). We enabled data collection using the ASQ in order to use these data to evaluate and refine the iterations for the informatics infrastructure. STAGE I, Part 3: We expanded the functionality of the informatics infrastructure by testing its ability to incorporate live (ongoing) longitudinal data collected from multiple forms and data sources obtained during the STAGE II study. The addition of these data allowed the COMET Steering Committee to create use cases with a greater diversity of data content. The STAGE II data were used to evaluate and refine the iterations for the expanded informatics infrastructure. STAGE I, Part 4: Part 4 was designed to expand the collection of data beyond individual research studies, tapping into University-wide systems (e.g., Stride) to link longitudinal data collected during research studies to longitudinal data collected during clinical visits. Only de-identified data were shared with the network, and only the local site held the codebook that translated the Global Identifier (ID) to the Participant ID. All Health Insurance Portability and Accountability Act (HIPAA) regulations were considered. STAGE II: This stage was comprised of the multicenter, randomized, parallel group, comparative effectiveness trial to compare positive airway pressure (PAP) vs. oral appliance (OA) therapy in improving hypertension and abnormalities in cardiovascular function in overweight/obese patients with obstructive sleep apnea (OSA). Data collected during the STAGE II study were incorporated in Part 3 of the STAGE I study. This comparative effectiveness trial was conducted at 4 clinical centers, and the data collected during this trial were used to test the electronic network informatics infrastructure. The primary aim of the Stage II CET was to evaluate and compare the effect of positive airway pressure and oral appliance therapy on 24-hour blood pressure and vascular structure and function associated with obstructive sleep apnea in a primarily female, overweight/obese hypertensive population. STAGE III: This stage was comprised of completion of data analysis and preparation of the electronic network informatics infrastructure for deployment beyond the four Clinical Centers to interested Clinical and Translational Science Awards (CTSA) institutions. We also explored expanding the ontologies beyond a sleep-related ontology to other medical ontologies, and the use of federated database methodology.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Sleep Apnea, Obstructive

Keywords

Obstructive Sleep Apnea, Obstructive Sleep Apnea Syndrome, Sleep Apnea Syndrome, Obstructive, Syndrome, Obstructive Sleep Apnea, Syndrome, Sleep Apnea, Obstructive, Syndrome, Upper Airway Resistance, Sleep Apnea, Upper Airway Resistance Sleep Apnea Syndrome

7. Study Design

Primary Purpose

Treatment

Study Phase

Not Applicable

Interventional Study Model

Parallel Assignment

Masking

None (Open Label)

Allocation

Randomized

Enrollment

131 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Positive Airway Pressure

Arm Type

Active Comparator

Arm Description

Participants randomized to standard clinical Positive Airway Pressure (PAP) treatment for Obstructive Sleep Apnea (OSA).

Arm Title

Oral Appliance

Arm Type

Active Comparator

Arm Description

Subjects randomized to standard Oral Appliance (OA) treatment for Obstructive Sleep Apnea (OSA).

Intervention Type

Device

Intervention Name(s)

Positive Airway Pressure (PAP)

Other Intervention Name(s)

Auto-titrating PAP (APAP), Continuous PAP (CPAP)

Intervention Description

Participants randomized to the Positive Airway Pressure treatment group received adequate Positive Airway Pressure (PAP) pressure therapy by a PAP titration study and used the device for 6 months.

Intervention Type

Device

Intervention Name(s)

Oral Appliance (OA)

Other Intervention Name(s)

Mandibular Advancement Device

Intervention Description

Participants randomized to the Oral Appliance treatment group received a dental evaluation to determine the optimal setting for the Oral Appliance (OA), and used the appliance for 6 months.

Primary Outcome Measure Information:

Title

Nocturnal Mean Arterial Blood Pressure (NMAP) at 2 Months

Description

Mean arterial blood pressure during the sleep period as recorded by 24-hour ambulatory blood pressure monitoring after approximately 2 months of treatment

Time Frame

2 months

Secondary Outcome Measure Information:

Title

Nocturnal Mean Arterial Blood Pressure (NMAP) at 6 Months

Description

Nocturnal mean arterial blood pressure as recorded by 24-hour ambulatory blood pressure monitoring after approximately 6 months of treatment

Time Frame

6 months

Title

Ratio of Nocturnal Mean Arterial Pressure (NMAP) to Daytime Mean Arterial Pressure at 2 Months

Description

Time Frame

2 months

Title

Ratio of NMAP to Daytime Mean Arterial Pressure at 6 Months

Description

Time Frame

6 months

Title

Mean Absolute Flow-Mediated Vasodilatation of the Brachial Artery by Vascular Ultrasound

Description

Time Frame

6 months

Title

Mean Relative Flow-Mediated Vasodilatation of the Brachial Artery by Vascular Ultrasound

Description

Time Frame

6 months

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Age > 18 years. BMI > = 25.0 kg/m^2. A diagnosis of obstructive sleep apnea based upon medical history and apnea- hypopnea index > = 10.0 or oxygen desaturation index (ODI; ≥4%) ≥ 10.0 on Diagnostic Polysomnogram. Report a history of hypertension (or need for treatment for hypertension) which is currently untreated OR taking medication for the treatment of hypertension. Stable medication regimen for 2 months prior to the Baseline Testing Visit. As-needed medications such as those used for allergy, cold, or minor pain symptoms may be used at the discretion of the Clinical Center physician. Exclusion Criteria: Cardiovascular disease which, in the judgment of the investigator, if observed during standard clinical practice would lead the treating physician to make every effort to treat the patient's sleep apnea with positive airway pressure, rather than alternative treatments. Clinically significant acute or chronic disease that is not well controlled or could affect ability to complete or comply with study procedures, in the opinion of the Clinical Center physician. Respiratory disease requiring supplemental oxygen or medication. Individuals with asthma may be included at the discretion of the Clinical Center physician if disease is well controlled and medications are stable for 2 months. History of (within 12 months prior to enrollment), or current diagnosis of, Axis I or Axis II psychiatric disorder (other than obstructive sleep apnea) that in the opinion of the Clinical Center physician would affect ability to complete or comply with study procedures (e.g., schizophrenia and other psychotic disorders). History of (within 3 months prior to enrollment), or current diagnosis of narcolepsy, idiopathic hypersomnia, restless legs syndrome, rapid eye movement (REM) behavior disorder, persistent situational insomnia, or sleep-related breathing disorders other than obstructive sleep apnea. Periodic limb movement arousal index > 10.0 on the Diagnostic Polysomnogram. Significant daytime sleepiness at study entry as indicated by: an Epworth Sleepiness Scale total score > 16, or a score of 3 (high chance) on the question about risk of dozing "In a car, while stopped for a few minutes in traffic" or a report of falling asleep at the wheel, a motor vehicle accident, or near-miss accident due to sleepiness in the past 24 months, which in the judgment of the study physician was not attributable to acute sleep loss. Oxygen saturation < 80% for > 10% of sleep time during the Diagnostic Polysomnogram, or intervention with positive airway pressure or oxygen for safety purposes during the Diagnostic Polysomnogram. Any prior treatment for obstructive sleep apnea with positive airway pressure or oral appliance, or surgical treatment for obstructive sleep apnea in the past year. Contraindication for treatment with either positive airway pressure or oral appliance, in the opinion of the Clinical Center physician or dentist, including significant nasal obstruction, insufficient or loose teeth, dentures, advanced periodontal disease, or significant temporomandibular joint pain. Pregnancy. Difficulty understanding or speaking English, or inability to read and understand informed consent and study procedures. Significant vision, hearing, or motor problems that, in the opinion of the Clinical Center physician, would affect ability to complete study procedures. A work schedule that does not allow for nighttime sleep on the 3 nights before each study visit. Current or planned participation in another research study. Metal objects, devices, or implants that are in or on the body (Stanford Clinical Center only). Creatinine clearance <30 and creatinine >1.6 (Stanford Clinical Center only). Upper arm circumference > 20 inches

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Clete A Kushida, MD, PhD

Organizational Affiliation

Stanford University

Official's Role

Study Director

First Name & Middle Initial & Last Name & Degree

Allan Pack, MD

Organizational Affiliation

Center for Sleep, University of Pennsylvania School of Medicine

Official's Role

Principal Investigator

First Name & Middle Initial & Last Name & Degree

Susan Redline, MD

Organizational Affiliation

Harvard Brigham and Women's Hospital

Official's Role

Principal Investigator

First Name & Middle Initial & Last Name & Degree

Ruth Benca, MD

Organizational Affiliation

University of Wisconsin-Madison School of Medicine

Official's Role

Principal Investigator

Facility Information:

Facility Name

Stanford Sleep Medicine Center

City

Redwood City

State/Province

California

ZIP/Postal Code

94063

Country

United States

Facility Name

Harvard Brigham and Women's Hospital

City

Boston

State/Province

Massachusetts

ZIP/Postal Code

02115

Country

United States

Facility Name

Center for Sleep and Circadian Neurobiology, University of Pennsylvania School of Medicine

City

Philadelphia

State/Province

Pennsylvania

ZIP/Postal Code

19104

Country

United States

Facility Name

University of Wisconsin-Madison School of Medicine, Department of Psychiatry

City

Madison

State/Province

Wisconsin

ZIP/Postal Code

53719

Country

United States

12. IPD Sharing Statement

Plan to Share IPD

Citations:

PubMed Identifier

8464434

Citation

Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993 Apr 29;328(17):1230-5. doi: 10.1056/NEJM199304293281704.

Results Reference

background

PubMed Identifier

25848590

Citation

Nichols DA, DeSalvo S, Miller RA, Jonsson D, Griffin KS, Hyde PR, Walsh JK, Kushida CA. The COMET Sleep Research Platform. EGEMS (Wash DC). 2014 Nov 24;2(1):1059. doi: 10.13063/2327-9214.1059. eCollection 2014.

Results Reference

background

Learn more about this trial

Comparative Outcomes Management With Electronic Data Technology (COMET) Study

We'll reach out to this number within 24 hrs